Comprehensive analysis of PD‐L1 in non‐small cell lung cancer with emphasis on survival benefit, impact of driver mutation and histological types, and archival tissue
CC Wang, KT Huang, HC Chang, CC Tseng… - Thoracic …, 2022 - Wiley Online Library
Background The aim of the study was to assess programmed death‐ligand‐1 (PD‐L1)
expression in different histological types and gene mutation status of patients with non‐small …
expression in different histological types and gene mutation status of patients with non‐small …
Clinicopathological and molecular characteristics associated with PD-L1 expression in non-small cell lung cancer: a large-scale, multi-center, real-world study in …
Q Zheng, Y Huang, X Zeng, X Chen, S Shao… - Journal of Cancer …, 2021 - Springer
Purpose The study aimed to evaluate the clinicopathological and molecular profiles
associated with programmed death ligand 1 (PD-L1) expression in non-small cell lung cell …
associated with programmed death ligand 1 (PD-L1) expression in non-small cell lung cell …
[HTML][HTML] Unique distribution of programmed death ligand 1 (PD-L1) expression in East Asian non-small cell lung cancer
Y Pan, D Zheng, Y Li, X Cai, Z Zheng, Y Jin… - Journal of Thoracic …, 2017 - ncbi.nlm.nih.gov
Background To determine the proportion and clinical features of programmed death ligand 1
(PD-L1) expression in East Asian non-small cell lung cancer (NSCLC). Methods PD-L1 …
(PD-L1) expression in East Asian non-small cell lung cancer (NSCLC). Methods PD-L1 …
Association with PD-L1 expression and clinicopathological features in 1000 lung cancers: a large single-institution study of surgically resected lung cancers with a …
Programmed cell death ligand 1 (PD-L1) expression is an important biomarker for predicting
response to immunotherapy in clinical practice. Hence, identification and characterization of …
response to immunotherapy in clinical practice. Hence, identification and characterization of …
[HTML][HTML] Clinical significance of PD-L1 protein expression in surgically resected primary lung adenocarcinoma
K Takada, T Okamoto, F Shoji, M Shimokawa… - Journal of Thoracic …, 2016 - Elsevier
Introduction The clinicopathological features of carcinomas expressing programmed death
ligand 1 (PD-L1) and their associations with common driver mutations, such as mutations in …
ligand 1 (PD-L1) and their associations with common driver mutations, such as mutations in …
[HTML][HTML] Correlation between PD-L1 expression and clinicopathological characteristics of non-small cell lung cancer: a real-world study of a large Chinese cohort
Y Jin, X Shen, Y Pan, Q Zheng, H Chen… - Journal of thoracic …, 2019 - ncbi.nlm.nih.gov
Background Programmed death ligand-1 (PD-L1) is a predictive marker of anti-programmed
death protein 1 (PD-1)/PD-L1 therapies for non-small cell lung cancer (NSCLC). However …
death protein 1 (PD-1)/PD-L1 therapies for non-small cell lung cancer (NSCLC). However …
Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma
Z Song, X Yu, G Cheng, Y Zhang - Journal of translational medicine, 2016 - Springer
Background Several clinical trials have shown that immune treatment focus on programmed
death-1 and programmed death-ligand 1 (PD-L1) yields a good clinical efficacy in advanced …
death-1 and programmed death-ligand 1 (PD-L1) yields a good clinical efficacy in advanced …
Association of PD‐L1 expression with driver gene mutations and clinicopathological characteristics in non‐small cell lung cancer: A real‐world study of 10 441 …
G Ruiz, D Enrico, YD Mahmoud, A Ruiz… - Thoracic …, 2024 - Wiley Online Library
Background Programmed death ligand‐1 (PD‐L1) expression is a well‐known predictive
biomarker of response to immune checkpoint blockade in non‐small cell lung cancer …
biomarker of response to immune checkpoint blockade in non‐small cell lung cancer …
PD-L1 expression and comprehensive molecular profiling predict survival in nonsmall cell lung cancer: a real-world study of a large Chinese cohort
Y Jin, Q Xue, X Shen, Q Zheng, H Chen, X Zhou, Y Li - Clinical lung cancer, 2022 - Elsevier
Background Programmed death ligand 1 (PD-L1) expression is the current standard
biomarker used to predict non-smallcell lung cancer (NSCLC) response to immunotherapy …
biomarker used to predict non-smallcell lung cancer (NSCLC) response to immunotherapy …
Correlation of programmed death-ligand 1 expression with gene expression and clinicopathological parameters in Indian patients with non-small cell lung cancer
M Kumar, B Guleria, S Swamy, S Soni - Lung India, 2020 - journals.lww.com
Objectives: The aim of this study is to evaluate the incidence of programmed cell death-
ligand 1 (PD-L1) expression in non-small cell lung cancer (NSCLC) cases and its correlation …
ligand 1 (PD-L1) expression in non-small cell lung cancer (NSCLC) cases and its correlation …
相关搜索
- lung adenocarcinoma pd l1
- survival benefit histological types
- pd l1 histological types
- pd l1 survival benefit
- archival tissue histological types
- driver mutation histological types
- driver mutation survival benefit
- pd l1 archival tissue
- archival tissue survival benefit
- pd l1 driver mutation
- comprehensive analysis histological types
- comprehensive analysis survival benefit
- pd l1 comprehensive analysis
- archival tissue driver mutation
- archival tissue comprehensive analysis
- comprehensive analysis driver mutation